These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 37801267)

  • 41. 4. The use and misuse of performance-enhancing substances in sport.
    Orchard JW; Fricker PA; White SL; Burke LM; Healey DJ
    Med J Aust; 2006 Feb; 184(3):132-6. PubMed ID: 16460300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Moral Foundation for Anti-Doping: How Far Have We Progressed? Where Are the Limits?
    Murray TH
    Med Sport Sci; 2017; 62():186-193. PubMed ID: 28571014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dietary supplements containing prohibited substances.
    van der Bijl P; Tutelyan VA
    Vopr Pitan; 2013; 82(6):6-13. PubMed ID: 24741950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mass spectrometry in sports drug testing-Analytical approaches and the athletes' exposome.
    Thevis M; Görgens C; Guddat S; Thomas A; Geyer H
    Scand J Med Sci Sports; 2024 Jan; 34(1):e14228. PubMed ID: 36539355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Supplement usage and doping attitudes in elite youth sports: The mediating role of dietary supplement acceptance.
    Kristensen JÅ; Haugen T; Ommundsen Y
    PLoS One; 2024; 19(2):e0297078. PubMed ID: 38300939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. True Dopers or Negligent Athletes? An Analysis of Anti-Doping Rule Violations Reported to the World Anti-Doping Agency 2010-2012.
    de Hon O; van Bottenburg M
    Subst Use Misuse; 2017 Dec; 52(14):1932-1936. PubMed ID: 28742405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
    Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
    J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anabolic agents: recent strategies for their detection and protection from inadvertent doping.
    Geyer H; Schänzer W; Thevis M
    Br J Sports Med; 2014 May; 48(10):820-6. PubMed ID: 24632537
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of emerging patterns of drug misuse in sports via wastewater monitoring: A mini-review and potential strategies.
    Chang WC; Hsu MC; Liao PC
    Environ Pollut; 2023 Sep; 333():122087. PubMed ID: 37348696
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards an empirical model of performance enhancing supplement use: a pilot study among high performance UK athletes.
    Mazanov J; Petróczi A; Bingham J; Holloway A
    J Sci Med Sport; 2008 Apr; 11(2):185-90. PubMed ID: 17350333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Attitudes and doping: a structural equation analysis of the relationship between athletes' attitudes, sport orientation and doping behaviour.
    Petróczi A
    Subst Abuse Treat Prev Policy; 2007 Nov; 2():34. PubMed ID: 17996097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating the elite athlete: anti-doping information for the health professional.
    Tandon S; Bowers LD; Fedoruk MN
    Mo Med; 2015; 112(2):122-8. PubMed ID: 25958657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
    Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
    Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prevention of doping and the improper use of drugs and food supplements in sports and physical activities: a survey on the activity of the prevention departments of Italian local health authorities.
    Pasquarella C; Pompili M; Valeriani F; Morgado M; Milicia GM; Veronesi L; Odone A; Zoni R; Saccani E; Savino G; Persi Y; Pinelli M; Liguori G; Gallè F; Di Onofrio V; Fallace P; Romano Spica V; ; ;
    Ann Ig; 2019; 31(6):533-547. PubMed ID: 31616898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug misuse in sport: a New Zealand perspective.
    Curtis A; Gerrard D; Burt P; Osborne H
    N Z Med J; 2015 Dec; 128(1426):62-8. PubMed ID: 26913908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. N,N-dimethyl-2-phenylpropan-1-amine - new designer agent found in athlete urine and nutritional supplement.
    Kwiatkowska D; Wójtowicz M; Jarek A; Goebel C; Chajewska K; Turek-Lepa E; Pokrywka A; Kazlauskas R
    Drug Test Anal; 2015 Apr; 7(4):331-5. PubMed ID: 25355281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Medicolegal aspects of doping in sports].
    Pruvost J; Depiesse F
    Ann Readapt Med Phys; 2004 Aug; 47(6):263-73. PubMed ID: 15297116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current situation and measures to promote anti-doping activities in Japan].
    Asakawa S
    Yakugaku Zasshi; 2011; 131(12):1755-6. PubMed ID: 22129872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of banned substance residue analysis in the control of dietary supplement contamination.
    Judkins CM; Teale P; Hall DJ
    Drug Test Anal; 2010 Sep; 2(9):417-20. PubMed ID: 20812298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.